Fingolimod

Expert Voices: Understanding pediatric multiple sclerosis research and care

In this installment of our ā€œExpert Voicesā€ series, Multiple Sclerosis News Today asked Tanuja Chitnis, MD, to answer some of your questions about pediatric multiple sclerosis (MS). Chitnis is a board-certified neurologist specializing in multiple sclerosis-related neuroimmunological disorders. Chitnis’s interest in children with MS led her to create…

Marriage, Education, DMT Affect Patients’ Treatment Adherence

Among people with relapsing-remitting multiple sclerosis (RRMS), those who are married and have more formal education are more likely to take treatments as recommended, according to a new study from Iran. The study, “Effects of Disease-Modifying Treatments discontinuation in patients with Relapsing-Remitting Multiple Sclerosis: A 5…

3D Showing of Mayzent Binding to Receptor Could Advance Treatments

For the first time, researchers have brought to light the precise three-dimensional structure ofĀ Mayzent (siponimod) as it binds to its molecular target, the sphingosine 1-phosphate receptor 1 (S1P1). These findings are expected to aid in developing next-generation MS therapeutics with better selectivity for S1P1, enhancing their potency while reducing…

#ACTRIMS2022 ā€“ Algorithm Predicts Relapse Risk Using EHR Data

Using a two-step machine learning strategy, researchers have developed an algorithm to predict the risk of multiple sclerosis (MS) relapse based on data gleaned from electronic health records. “The two-step machine learning model predicts a patient’s future one-year MS relapse risk with clinically actionable accuracy, comparable to other clinical…

MS Hiker Laces Up Her Boots for Appalachian Trail

Reservations at a base lodge have been made, and a starting date is circled on her calendar. MS hiker April Hester is ready to start up the Appalachian Trail in the eastern U.S. It’s always an uphill hike for April, even when the trail is flat. She was diagnosed with…

COVID Booster May Benefit Patients on Anti-CD20 Therapy

Multiple sclerosis (MS) patients with weak immune responses to COVID-19 vaccines are more likely to respond successfully to the booster shot if they are receiving an anti-CD20 therapy compared with those on Gilenya (fingolimod), according to a small study in Norway. These early findings suggest that booster shots…

Gilenya Started Earlier in RRMS Disease Course in Recent Years

People with relapsing-remitting multiple sclerosis (RRMS) have switched to treatment with Gilenya (fingolimod) at an earlier stage in their disease in recent years, compared to individuals who switched to the treatment around the time it became available, a new study indicates. The findings suggest “an increased experience in…

Safety of Oral DMTs for RRMS in Real-world Use Seen to Match Trial Findings

People with relapsing-remitting multiple sclerosis (RRMS) using approved oral disease-modifyingĀ therapiesĀ generally tolerate the treatments well, with real-world adverse event profiles similar to those seen in clinical trials, an analysis of U.S. data indicates. Results also suggest high adherence to these therapies ā€” meaning patients are usually taking the therapies…

Ocrevus and PML: Should We Be Worried?

The journal JAMA Neurology recently reported that a 78-year-old man with progressive multiple sclerosis died after being diagnosed with progressive multifocal leukoencephalopathy (PML), a brain disease. The man, diagnosed with MS about 30 years ago, had been treated for two years with Ocrevus (ocrelizumab), and had no previous…

Lipid Signaling Molecule Regulates Immune Responses in Mice

Lipid (fat) molecules can function as chemical couriers, taking messages from tissue to tissue, organ to organ as part of the body’s immune defense guidance system. But in certain diseases such as multiple sclerosis (MS), the courier service may go awry. One such lipid molecule, called sphingosine 1-phosphate (S1P),…

Tysabri Superior to Gilenya at Easing Activity in RRMS, Study Reports

Treatment with Tysabri (natalizumab) was more effective thanĀ Gilenya (fingolimod) in helping people with relapsingā€“remitting multiple sclerosis (RRMS) achieve no evidence of disease activity, a head-to-head study suggested. The study, “BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS,” was…